Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Docetaxel remains a cornerstone of therapy for the patient with metastatic castration-resistant prostate cancer (CRPC). However, the landscape of CRPC therapy is changing rapidly – recently, data from the phase III TROPIC study revealed a survival advantage with the novel taxane cabazitaxel/predniso...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Sumanta Kumar, Twardowski, Przemyslaw, Sartor, Oliver
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998247/
https://www.ncbi.nlm.nih.gov/pubmed/21152241
http://dx.doi.org/10.2147/CIA.S14570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998247/
https://www.ncbi.nlm.nih.gov/pubmed/21152241
http://dx.doi.org/10.2147/CIA.S14570

Ejemplares similares